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Persistence of ''Australia Antigenemia"
in Mentally Retarded Children
Seven Years After Virus Hepatitis
Hajime Hayashi, Ph.D.* and Gerald A. LoGrippo, M.D.*

Australia antigen and antibody were assayed in acute and convalescent (1, 4 and 6
months) phase sera from 80 children with infectious hepatitis in an institution for
the mentally retarded. A higher incidence of Australia antigenemia was found in
18 of 40 (45%) mongoloid children as compared to 9 of 40 (23%)
non-mongoloid
chddren. Australia antigen persisted 7 years after the hepatitis epidemic in 11 mongoloid and 2 non-mongoloid children with hepatitis. None of the hepatitis group,
with or without Australia antigenemia, demonstrated precipitable antibody to the
Australia antigen. The discussion emphasizes the lack of virologic and immunologic
evidence relative to: (1) the specific association of Australia antigenemia to virus
hepatitis of the serum variety, (2) the persistence of Australia antigenemia in mongoloids associated with transaminase elevations, and (3) the specificity of Australia
antigenemia to the hepatitis virus particle and/or protein.

Although the properties of the Australia antigen are yet to be adequately
characterized, it is being hypothesized
that the antigen is closely associated
with virus hepatitis,- " and is a specific
virus antigen of the serum hepatitis
(SH) strainCs).^*"^ The frequency of
Australia antigenemia is reported in individuals with SH,-" infectious hepatitis (IH),-' -' '^-!" mongolism-«.io.ii and
certain clinical entities-'"•''•i*' as weU as
the normal population.- '* "'^'!''
In this report, the frequency and per-

sistence of the Australia antigenemia
were re-evaluated 7 years after the initial epidemic in 80 mentaUy retarded
chUdren in a 1962 institutional outbreak of virus hepatitis. In addition,
three other biochemical tests compared
in this report with the Australia antigen and antibody are: immunologulinM (IgM), serum transaminase levels
(SGPT and/or SGOT) and C-reactive
protein (CRP).
Materials and Methods
Clinical patients. Eighty of 652 mentaUy retarded institutionalized* chUdren
(1-15 years of age in 1962) had clini-
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cal signs and symptoms of virus hepatitis associated with jaundice, elevated
serum transaminase levels and elevated
serum immunoglobulin values (Igs;
IgM, IgG and IgA).!^." The hepatitisafflicted patients were in a relatively
new institudon. The outbreak was the
institution's first epidemic and was
classified as I H on the basis of its short
incubation period, the parenteral route
of infection and the abrupt nature of
the epidemic.i^
Serum specimens were coUected
during the acute phase of hepatitis and
at one, three to four and six to seven
months after the clinical onset. Serum
Ig levels and SGPT values were assayed in 1962 in the relatively fresh
state and reported elsewhere." However, the Australia antigen and antibody assays as well as CRP were performed on these sera in 1969 from
frozen stored (—20 C) specimens. In
1969, fresh sera were collected from
42 of the 80 inmates for re-evaluation
and all determinations were made on
fresh, unfrozen specimens.
Determination oj serum proteins
and enzyme. An immuno-chemical
method of analysis^* is used for determining serum proteins (Igs, CRP, Australia antigen and antibody). It is a
quantitative micro-double diffusion in
agar-slide technic employing a fivehole, plastic-template instead of making
holes in agar. By this technic, Igs and
CRP values are determined in mUligram per 100 ml of serum. The normal
values established for this laboratory
are: IgM (30-120 mg/100 m l ) ; " and
CRP-Negative (less than non-detectable quantities).1° The Australia antigen and antibody are also determined
by the same immuno-diffusion technic

using a seven-hole, plastic template.
AU precipitation bands are identified
with known antigen and antibody reactants. It is important to emphasize
that hemophUiac and hepatitis patients
carry a variety of precipitable reactants other than the Australia antigen
and antibody in their sera. These reactants must be differentiated by specific Australia antigen and antibody.
Serum transaminase (SGPT and/or
SGOT) are performed on fresh serum
by a clinical biochemistry laboratory;
normal values are less than 40 units
per ml.
Results
Since a high incidence of Australia
antigenemia was found in stored, frozen sera from chUdren with hepatitis
among institutional mongoloids, reevaluation of the data became necessary with fresh sera from those individuals. In addition, Australia antigen
positive tests warranted re-evaluation
for comparative study with other biochemical tests associated with virus
hepatitis.
Table I gives the number and percentage of Australia antigen positive
serum in chUdren with virus hepatitis in
1962; 40 were mongoloids (Down's
syndrome) and 40 nonmongoloids
(other mentally retarded chUdren). The
Australia antigen was positive during
the icteric stage in 18 of 40 (45%)
mongoloids and 9 of the 40 (23%)
nonmongoloids. The higher average incidence of Australia antigenemia in
these chUdren (34%) is influenced by
the number of mongoloids in this epidemic (45% in mongoloids and 23%
in the other chUdren). No specific precipitable antibody to Australia antigen
28
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Table I

AUSTRALIA ANTIGEN AND ANTIBODY
IN INFECTIOUS HEPATITIS

Entities

Total

Positive
Au-Ag*

Positive
Au-Ab*

Down's
Syndrome

40

18(45%)

0**

Others

40

9 (23%)

0**

Total

80

27(34%)

0

* Australia antigen (Au-Ag) and Australia antibody (Au-Ab).
** Australia antibody was negative during 2-6 months convalescence.
was detected in any of these chUdren
during the six months' convalescent
study.
Table I I gives the number of chUdren re-evaluated in 1969 and shows
the number of mongoloids and nonmongoloids persisting with Australia
antigenemia seven years after hepatitis.
In 1969, only 42 of the 80 chUdren
(23 mongoloids and 19 nonmongoloids) were avaUable for study. In 12
of 23 mongoloids who were positive
for Australia antigen in 1962, 11 of
these persisted with Australia antigenemia in 1969. In addition, five other
mongoloids with hepatitis (who were
negative with Australia antigen in
1962) became positive by 1969.

Among 19 nonmongoloid chUdren
with hepatitis, five of these were positive for Australia antigen in 1962 but
only two persisted with detectable antigenemia in 1969. In addition, two of
the nonmongoloid children with hepatitis in 1962, who were Australia antigen negative during six months' foUowup, were found to be positive in 1969.
In Table I I I , Australia antigenemia
is compared with three serum biochemical changes associated with acute
stages of virus hepatitis: SGPT, IgM
and CRP. In the 80 chUdren studied,
SGPT values are most consistently elevated, IgM elevation is next, foUowed
by CRP and Australia antigenemia.
The Australia antigenemia was not de29
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Table II
PERSISTENCE OF AUSTRALIA ANTIGENEMIA
7 YEARS AFTER HEPATITIS EPIDEMIC
Number of Patients
Clinical
Entities

Australia Antigenemia
Negative 1962 and
Positive
Positive 1969
(1969)

Total
-

Positive
(1962)

Down's
Syndrome

23

12

Others

19

5

11(48%)

5* (22%)
2*

2

Seven patients with hepatitis in 1962 were negative to Australia
antigen for 1 - 4 and 6 months post hepatitis. However, these
became Australia antigen positive during the interval indicated.

Table III
AUSTRALIA ANTIGENEMIA AND OTHER SERUM TESTS
IN INFECTIOUS HEPATITIS
Number of Icteric Patients
Total
80
(% positive)

SGPT|*

IgM 1*

CRP+ *

Au-Ag+ *

70

49

40

27

(88%)

(61%)

(50%)

(34%)

* Serum qlutamic pyruvic transaminase (SGPT), immunoglobulin-M
(IqM), CT-reactive protein (CRP) and Australia antigen (Au-Ag).
(+) or ( t ) signs indicate serum values above normal levels.
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days).^ *''^* Our data support the association of Australia antigenemia with
infectious hepatitis (IH) of the short incubation form (less than 40 days). In
our study, the institutional outbreak of
virus hepatitis was of the I H variety,
considering the clinical aspects of the
disease, short incubation period, parenteral route of infection and the
abrupt onset and termination of the
epidemic.^"'^-^ Australia antigenemia
was found in 27 of 80 inmates (34%)
with clinical jaundice. In addition,
serum transaminase (SGPT) and serum
immunoglobulins (IgM and IgG) were
also elevated above normal values. The
epidemiologic and clinical features of
the outbreak indicated the infectious
variety of hepatitis. Although we could
not classify the epidemic as moderately
contagious, since 34% of the icteric
cases demonstrated Australia anti-

tectable in 66% of the chUdren during
the acute stage of virus hepatitis, thus
indicating Australia antigenemia to be
the least sensitive test of the four
studied. Table I V shows further analysis of these tests. There is lack of correlation among IgM, CRP and Australia antigenemia during the acute and
six months' convalescent study, with
percentages varying considerably. This
is true whether the tests are compared
individually or in combinations, as
shown. These tests appear to reflect the
host's responses to nonspecific inflammatory conditions.
Discussion
The literature emphasizes the association of Australia antigenemia with
serum hepatitis (SH) of the long incubation form of virus hepatitis (41-108

Table IV
LACK OF CORRELATION BETWEEN AUSTRALIA ANTIGENEMIA AND
HOST'S INFLAMMATORY RESPONSES IN INFECTIOUS HEPATITIS
Tests Positive

Percent in 80 Children
Acute
Convalescence (6 mos.)

None (Normal values)

19.5

43.4

IgM A*

Au-Ag+ *

14.6
15.9
7.3

13.2
9.2
15.8

Au-Ag +
Au-Ag +

17.1
1.2
8.5

1.3
6.6
6.6

Au-Ag+

15.9

3.9

1

IgMf

CRP+ '
CRP +
CRP+ ,

IgM A,
IgMj,

CRP+ ,

* See footnote in Table
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plement fixing antibody titers (1:5 or
less) in a small percentage (3 of 22) of
hepatitis patients, with no detectable
antibody precipitable to Australia antigen. In our study with serial serum
specimens at one, four and six months
after acute hepatitis, none of the 27
chUdren with Australia antigenemia
converted to positive precipitable antibody. Moreover, Australia antibody of
the precipitable type has not been demonstrated in 57 adult hepatitis patients
with Australia antigenemia.^^ There is
need for more serological evidence of
the specificity of this antigen to the
etiological agent or agents because of
the lack of sero-conversion to detectable precipitable antibody in hepatitis
patients with Australia antigenemia
and the small percentage of patients
with low complement fixing antibody
titers.
Based upon clinical criteria, serum
or infectious varieties of virus hepatitis
cannot be satisfactorily differentiated
as to incubation period, route of infection or administration of blood and
blood products. Both varieties are
transmitted by parenteral and oral
routes.^ ^'i® As documented in the Willowbrook institution by Krugman and
associates,!^ incubation periods are suitable criteria when initial exposures are
under investigational control. However,
in clinical cases, the majority of patients are unclassified since blood and
blood products may contain either
variety. The incubation period and onset of clinical signs and symptoms often
faU mid-zone (30-50 days) between the
two varieties. Since our institutional
and clinical studies with I H patients
also demonstrate Australia antigenemia, the presence of this antigen is not

genemia, we questioned whether our
outbreak was I H or SH in nature. If
I H and SH varieties were both present
among patients, it would be difficult to
explain in a relatively new institution
the mixed hepatitis varieties present
with abrupt onset and sudden termination in four to six weeks. Moreover, there has been no overt hepatitis
in this instUution since 1962. Whether
Australia antigenemia is associated
with the serum (long incubation) variety of hepatitis will remain unresolved
untU further immunologic and virologic evidence is obtained.
Sutnick et aP^ reported that in several large institutions the frequency
of Australia antigenemia was high
(27.7%) in patients with Down's syndrome and low (3.3%) in patients
without Down's syndrome. They also
reported that Australia antigen is associated with elevated SGPT values in
Down's syndrome. In our study, the
higher incidence of Australia antigenemia (45 % ) was also found in chUdren with Down's syndrome. There was
a lower incidence (23%) in the children with other abnormalities. In 1969,
the incidence of Australia antigenemia
among mongoloids (45%) during the
acute stage of I H became even higher
(70% from 45%). However, we do
not know how many of these chUdren
may have had Australia antigenemia
before the onset of hepatitis in 1962.
In contrast to Sutnick et al, transaminase levels in our chUdren with persisting Australia antigenemia were normal in 1969.
The literature emphasizes the specificity of the Australia antigen as a virus
protein on a hypothetical hasis.^'*-'^''--^
Shulman et aP^ ^i reported low com32

a reliable test for a differential diagnosis.
The conclusions being made in the
literature warrant more serologic and
virologic evidence relative to: (1) the
specific association of Australia antigenemia to virus hepatitis of the serum
variety;*'* (2) the persistence of Australia antigenemia in mongoloids associated with transaminase elevations;"
and (3) the specificity of Australia an-

tigenemia to the hepatitis virus particle
and/or protein.-'^'^'^-^i
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